Literature DB >> 2229279

Evaluation of the growth hormone-binding proteins in human plasma using high pressure liquid chromatography gel filtration.

A Tar1, J F Hocquette, J C Souberbielle, J P Clot, R Brauner, M C Postel-Vinay.   

Abstract

A technique using high pressure liquid chromatography gel filtration was used to evaluate GH-binding proteins (BP) in human plasma; eluate was monitored for radioactivity in a gamma-detection system connected to a computer. Plasma (200 microL) was incubated with [125I]human (h) GH (200,000 cpm) at 4 C for 20 h. The main GH-BP (peak II) was well separated from free [125I]hGH (peak III) and from a higher mol wt complex (peak I), which was minor. In our control plasma, the specific binding of [125I]hGH to peak II BP (II-BP) was 32.2 +/- 0.6% of the radioactivity. Scatchard analyses indicate an association constant of 3.6-7.4 X 10(8) M-1 and a binding capacity ranging from 24-86 ng/mL for peak II-BP in five normal adult plasma samples. Peak I material, separated from plasma of boys with pubertal delay, bound hGH with a low affinity (3 x 10(6) M-1) and a very high capacity (2 micrograms/mL). In cross-linking experiments, peak I appeared as two proteins of 165 and 174 kD; these mol wt were much higher than that of peak II-BP, previously estimated at 53,000. hGH complexed to peak II-BP remained fully immunoreactive with use of the anti-hGH antibodies of our assay. In plasma containing 10-20 micrograms/L hGH, the proportion of bound hormone (peak II) was 44.5 +/- 2.3%, whereas the amount of hGH in peak I was very low or undetectable. Specific binding of hGH to II-BP was lowest during the first year of life and highest in adulthood. No sex difference was found. I-BP is differentially regulated, since its binding activity was significantly lower in adults than in prepubertal children. Normal values for age should be taken into account to interpret GH-binding activity, particularly in children 2 yr of age or younger. Our GH binding assay offers important gains in terms of rapidity and resolution; it has permitted a clear separation and characterization of the two GH-binding components present in human plasma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229279     DOI: 10.1210/jcem-71-5-1202

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

2.  Serum growth hormone-binding protein is decreased in prepubertal children with idiopathic short stature.

Authors:  N Dávila; M Moreira-Andrés; J Alcañiz; B Barceló
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

3.  Lack of hormone binding in COS-7 cells expressing a mutated growth hormone receptor found in Laron dwarfism.

Authors:  M Edery; M Rozakis-Adcock; L Goujon; J Finidori; C Lévi-Meyrueis; J Paly; J Djiane; M C Postel-Vinay; P A Kelly
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

4.  Identification of prolactin and growth hormone binding proteins in rabbit milk.

Authors:  M C Postel-Vinay; L Belair; C Kayser; P A Kelly; J Djiane
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

5.  Plasma growth hormone-binding activity is low in uraemic children.

Authors:  M C Postel-Vinay; A Tar; H Crosnier; M Broyer; R Rappaport; B Tönshoff; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

6.  Growth hormone binding protein activity in obese children.

Authors:  S Seminara; A Filpo; F La Cauza; A Faedda; A Miola; S Pellizzone; M Casati; S Loche
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

7.  Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.

Authors:  D Haffner; F Schaefer; J Girard; E Ritz; O Mehls
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.